Abstract：Objective To study the effects of alprostadil combined with calcium dobesilate on transforming growth factor-β1 and immune function in patients with diabetic nephropathy.Methods A total of 100 patients with diabetic nephropathy who had received treatment in the hospital from February 2017 to February 2019 were enrolled in this study. The patients were divided into a study group and a control group according to the random number table, with 50 cases in each group. Based on the conventional treatment, the control group was treated with alprostadil and the study group was treated with alprostadil combined with calcium dobesilate. The response rate, serum inflammatory factors and TGF-β1, immune function and renal function were compared between the two groups.Results The response rate, the levels of CD4+, CD4+/CD8+ and the endogenous creatinine clearance rate were higher in the study group than in the control group, and the levels of CD8+, tumor necrosis factor-α, C-reactive protein, interleukin-6, TGF-β1, urea nitrogen and creatinine were all shown to be lower than the control group, with all the differences being statistically significant (P＜0.05). Conclusions For patients with diabetic nephropathy, alprostadil combined with calcium dobesilate can help improve the response rate, inhibit serum inflammatory factors, reduce the TGF-β1 level, and improve their immune function and renal function.
